Jennewein Biotechnologie GmbH acquires Arthus Mineralsprings Bad Hönningen to build a new integrated fermentation and recovery plant for human milk oligosaccharides

Rheinbreitbach/Germany (ots) - Jennewein Biotechnologie GmbH
announces that it has acquired the former facilities of Arthus
Mineralspring Company in Bad Hönningen (Rhineland-Palatine) in order
to expand the production of human milk oligosaccharides (HMOs). "We
have been searching for some time for a suitable location to
establish an integrated HMO fermentation and recovery plant close to
our current facility in Rheinbreitbach," states Dr. Stefan Jennewein
(CEO and co-founder, Jennewein Biotechnologie). "With the expansion
of our HMO portfolio, and the development of our HMO Mix product, we
need at least five new fermentation and recovery lines." Benedikt
Engels (Chief Operation Officer, Jennewein Biotechnologie) adds "With
the new plant, we will be able to produce additional HMOs, expanding
our current portfolio of two products (2?-fucosyllactose and
lacto-N-neotetraose) to include five more (3?-fucosyllactose,
difucosyllactose, lacto-N-tetraose, 6?-sialyllactose and
3?-sialyllactose)." The new integrated facility will combine
fermentation and recovery, and will yield spray-dried HMO products.
Jennewein Biotechnologie plans to build separate production lines for
the manufacture for each of the new HMO products. "With fermenters of
more than 200m3 each, the new plant will become one of the largest
fermentation facilities in central Europe," adds Stephan Michel
(Chief Financial Officer, Jennewein Biotechnologie).

About Jennewein Biotechnologie:

Jennewein Biotechnologie is a leading international industrial
biotechnology company with a range of products in the field of
complex oligosaccharides (HMOs) and rare monosaccharides. The company
manufactures an extensive portfolio of innovative HMO products, such
as 2?-fucosyllactose, 3?-fucosyllactose and lacto-N-tetraose. These
rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry.
The manufacturing process involves state-of-the-art fermentation
techniques. In 2015, the US Food and Drug Administration (FDA)
granted Jennewein Biotechnologie a license to market
2?-fucosyllactose in the USA. This was followed in 2017 by European
Union marketing authorisation under the Novel Food Regulation.

Press Contact:
Dr. Bettina Gutierrez
bettina.gutierrez@jennewein-biotech.de
02224/98810797

Original-Content von: Jennewein Biotechnologie GmbH, übermittelt durch news aktuell